NuCana plc (NCNA) Income Statement

NASDAQ: NCNARevenue, profits, margins and EPS over 10 years.

NCNA 2025 at a glance

Fiscal year ended December 31, 2025 · British pounds
Revenue
£0
2025 · hover or tap a bar for each year
2016: £02017: £283,0002018: £0 (−100.0%)2019: £02020: £02021: £02022: £02023: £02024: £02025: £0
20162025
Gross profit
−£267,994
2025 · hover or tap a bar for each year
2016: £02017: £283,0002018: £0 (−100.0%)2019: £02025: −£267,994
20162025
Operating income
−£20.1M
2025 · hover or tap a bar for each year
2016: −£8.4M2017: −£22.2M2018: −£22.0M2019: −£26.7M2020: −£36.4M2021: −£47.9M2022: −£39.1M2023: −£32.8M2024: −£22.8M2025: −£20.1M
20162025
Net income
−£29.4M
2025 · hover or tap a bar for each year
2016: −£6.0M2017: −£23.1M2018: −£13.8M2019: −£21.4M2020: −£30.7M2021: −£40.5M2022: −£32.0M2023: −£27.6M2024: −£19.0M2025: −£29.4M
20162025

NCNA revenue and net income

RevenueNet incomeNet margin (right axis)

NCNA profit margins

GrossOperatingNet

NCNA growth rates

to 2025
1 year3 years5 years10 years
Revenue————
Gross profit————
Operating income————
Net income————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

NCNA income statement in British pounds

NuCana plc annual income statement
2025202420232022202120202019201820172016
Revenue£0£0£0£0£0£0£0£0£283,000£0
Cost of revenue£267,994—————£0£0£0£0
Gross profit−£267,994—————£0£0£283,000£0
Research & development£12.7M£18.0M£25.1M£36.4M£36.8M£25.9M£19.7M£16.8M£17.7M£7.9M
Sales, general & admin£8.1M£5.0M£6.1M£7.3M£8.5M£7.0M£6.0M£5.2M£4.6M£1.1M
Total operating expenses£20.1M£22.8M£32.8M£39.1M£47.9M£32.9M£25.7M£22.0M£24.0M£9.0M
Operating income−£20.1M−£22.8M−£32.8M−£39.1M−£47.9M−£36.4M−£26.7M−£22.0M−£22.2M−£8.4M
Interest income£386,000£358,000£754,000£669,000£103,000£246,000£1.0M£1.1M£208,000£283,000
Interest expense£19,561—£1.1M£9.9M£5.0M£6.7M£989,000£0£0£0
Income before taxes−£30.5M−£22.5M−£32.0M−£38.5M−£47.8M−£36.2M−£25.7M−£18.1M−£25.5M−£8.2M
Income taxes−£1.2M−£3.5M−£4.4M−£6.4M−£7.3M−£5.5M−£4.2M−£4.2M−£2.4M−£2.1M
Net income−£29.4M−£19.0M−£27.6M−£32.0M−£40.5M−£30.7M−£21.4M−£13.8M−£23.1M−£6.0M
EBITDA−£20.6M−£22.5M−£30.6M−£43.0M−£44.4M−£28.6M£718,000£371,000£194,000£101,000
Gross margin————————100.0%—
Operating margin————————−7,860.8%—
Net margin————————−8,157.2%—

Quarterly columns are labeled by the month the quarter ended. Figures in British pounds as reported in NCNA's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

NCNA financial results

NuCana reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of £29.4 million. Figures are in British pounds, the currency of its financial statements.

See the NCNA stock overview for the latest quote and news, or the NCNA chart for price history and technical indicators.

NCNA income statement FAQ

Does NuCana have revenue?

NuCana reported no revenue for fiscal year 2025, which ended on December 31, 2025.

Is NuCana profitable?

No. NuCana reported a net loss of £29.4 million in fiscal 2025.

How much does NuCana spend on research and development?

NuCana spent £12.7 million on research and development in fiscal 2025.

When will NuCana report its next earnings?

NuCana is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.

When does NuCana's fiscal year end?

NuCana's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.

Biotechnology income statements